Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALXO NASDAQ:BDRX NASDAQ:INTS NASDAQ:KZR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALXOALX Oncology$0.59+13.2%$0.50$0.40▼$2.89$27.66M1.14541,524 shs310,088 shsBDRXBiodexa Pharmaceuticals$6.98+4.2%$9.46$5.85▼$166.93$24.48M0.98145,749 shs36,683 shsINTSIntensity Therapeutics$0.27-89.8%$0.00$0.26▼$4.94$5.99M3.256.23 million shs73,559 shsKZRKezar Life Sciences$4.10+1.2%$4.40$3.62▼$9.18$29.59M0.6575,741 shs42,227 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALXOALX Oncology+13.24%-6.28%+24.83%+16.87%-79.49%BDRXBiodexa Pharmaceuticals+4.18%-20.68%-19.40%-47.52%+697,999,900.00%INTSIntensity Therapeutics+10.83%-21.53%-11.04%-52.42%-94.45%KZRKezar Life Sciences+1.23%-5.96%-10.09%-1.44%-32.96%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALXOALX Oncology3.2774 of 5 stars3.43.00.00.01.14.21.3BDRXBiodexa Pharmaceuticals0.0851 of 5 stars0.02.00.00.01.40.00.0INTSIntensity Therapeutics2.5585 of 5 stars3.45.00.00.01.10.80.6KZRKezar Life Sciences3.5186 of 5 stars3.21.00.04.60.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALXOALX Oncology 2.83Moderate Buy$3.30462.47% UpsideBDRXBiodexa Pharmaceuticals 0.00N/AN/AN/AINTSIntensity Therapeutics 2.75Moderate Buy$6.752,437.59% UpsideKZRKezar Life Sciences 2.33Hold$39.50863.41% UpsideCurrent Analyst Ratings BreakdownLatest INTS, KZR, BDRX, and ALXO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/28/2025INTSIntensity TherapeuticsThinkEquitySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy7/16/2025KZRKezar Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/21/2025ALXOALX OncologyUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$1.20 ➝ $1.005/19/2025INTSIntensity TherapeuticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/9/2025ALXOALX OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $2.00(Data available from 8/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALXOALX OncologyN/AN/AN/AN/A$2.14 per shareN/ABDRXBiodexa Pharmaceuticals$470K54.21N/AN/A$2.91 per share2.40INTSIntensity TherapeuticsN/AN/AN/AN/A$0.19 per shareN/AKZRKezar Life Sciences$7M4.28N/AN/A$16.02 per share0.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALXOALX Oncology-$134.85M-$2.47N/AN/AN/AN/A-104.43%-77.74%8/14/2025 (Estimated)BDRXBiodexa Pharmaceuticals-$7.32MN/A0.00N/AN/AN/AN/AN/AN/AINTSIntensity Therapeutics-$16.27M-$1.07N/AN/AN/AN/A-527.85%-276.29%N/AKZRKezar Life Sciences-$83.74M-$10.82N/AN/AN/AN/A-61.15%-50.27%8/12/2025 (Estimated)Latest INTS, KZR, BDRX, and ALXO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ALXOALX Oncology-$0.46N/AN/AN/AN/AN/A8/12/2025Q2 2025KZRKezar Life Sciences-$2.25N/AN/AN/AN/AN/A5/13/2025Q1 2025INTSIntensity Therapeutics-$0.21-$0.22-$0.01-$0.22N/AN/A5/13/2025Q1 2025KZRKezar Life Sciences-$2.56-$2.27+$0.29-$2.27N/AN/A5/8/2025Q1 2025ALXOALX Oncology-$0.47-$0.58-$0.11-$0.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALXOALX OncologyN/AN/AN/AN/AN/ABDRXBiodexa PharmaceuticalsN/AN/AN/AN/AN/AINTSIntensity TherapeuticsN/AN/AN/AN/AN/AKZRKezar Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALXOALX Oncology0.095.475.47BDRXBiodexa Pharmaceuticals0.011.751.75INTSIntensity Therapeutics0.310.630.63KZRKezar Life Sciences0.047.097.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALXOALX Oncology97.97%BDRXBiodexa Pharmaceuticals17.51%INTSIntensity Therapeutics3.74%KZRKezar Life Sciences67.90%Insider OwnershipCompanyInsider OwnershipALXOALX Oncology21.00%BDRXBiodexa Pharmaceuticals0.34%INTSIntensity Therapeutics17.10%KZRKezar Life Sciences9.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALXOALX Oncology4053.40 million42.18 millionOptionableBDRXBiodexa Pharmaceuticals203.65 million3.64 millionNot OptionableINTSIntensity Therapeutics2,02125.07 million20.79 millionNot OptionableKZRKezar Life Sciences607.31 million6.63 millionNot OptionableINTS, KZR, BDRX, and ALXO HeadlinesRecent News About These CompaniesKezar sees hepatitis hold lifted, hints at resurrecting lupus programJuly 16, 2025 | fiercebiotech.comFFDA lifts partial hold on Kezar’s zetomipzomib trialJuly 16, 2025 | thepharmaletter.comTKezar Life Sciences Says FDA Lifts Clinical HoldJuly 16, 2025 | marketwatch.comKezar Life Sciences stock gains after FDA lifts partial clinical holdJuly 16, 2025 | uk.investing.comKezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune HepatitisJuly 15, 2025 | businesswire.comKezar Life Sciences Inc. Research & Ratings | KZR | Barron'sJuly 13, 2025 | barrons.comKZR | Kezar Life Sciences Inc. Stock Overview (U.S.: Nasdaq) - Barron'sJune 30, 2025 | barrons.comKezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock?May 27, 2025 | zacks.comKezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | businesswire.comKezar toplines small Phase 2a dataset in autoimmune liver diseaseMarch 27, 2025 | endpts.comEKezar Life Sciences price target lowered to $7 from $9 at Wells FargoMarch 27, 2025 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Roche Holding AG (OtherRHHVF), Kezar Life Sciences (KZR) and Axsome Therapeutics (AXSM)March 26, 2025 | markets.businessinsider.comKezar Life Sciences reports topline results from PORTOLA trialMarch 26, 2025 | markets.businessinsider.comKezar Life Sciences, Inc. (KZR) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call (Transcript)March 25, 2025 | seekingalpha.comKezar drops after Q4 results and mid-stage data for lead assetMarch 25, 2025 | msn.comKezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial ResultsMarch 25, 2025 | businesswire.comKezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025March 24, 2025 | businesswire.comTD Cowen Keeps Their Buy Rating on Kezar Life Sciences (KZR)February 28, 2025 | markets.businessinsider.comPositive Report for Kezar Life Sciences (KZR) from William BlairFebruary 28, 2025 | markets.businessinsider.comWilliam Blair Sticks to Its Hold Rating for Kezar Life Sciences (KZR)February 25, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonAmerica Wants Drone Dominance: Are These Stocks Ready to Soar?By Chris Markoch | July 20, 2025View America Wants Drone Dominance: Are These Stocks Ready to Soar?AMD Outperforming NVIDIA: What’s Behind It and Can It Continue?By Dan Schmidt | August 4, 2025View AMD Outperforming NVIDIA: What’s Behind It and Can It Continue?Top 220 Most Beloved Local Businesses Across the U.S. [2025 Survey]By MarketBeat Staff | July 29, 2025View Top 220 Most Beloved Local Businesses Across the U.S. [2025 Survey]Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost SharesBy Leo Miller | July 17, 2025View Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost SharesINTS, KZR, BDRX, and ALXO Company DescriptionsALX Oncology NASDAQ:ALXO$0.59 +0.07 (+13.24%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$0.98 +0.39 (+67.04%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.Biodexa Pharmaceuticals NASDAQ:BDRX$6.98 +0.28 (+4.18%) Closing price 08/4/2025 03:59 PM EasternExtended Trading$7.41 +0.43 (+6.16%) As of 05:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.Intensity Therapeutics NASDAQ:INTSIntensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.Kezar Life Sciences NASDAQ:KZR$4.10 +0.05 (+1.23%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$4.12 +0.02 (+0.37%) As of 04:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas How 2 Deals in 48 Hours Changed Everything for Joby Aviation Here's Why Traders Turned Bullish on Boeing Stock Onsemi’s August Pullback Is a Signal to Buy for Tech Investors Strategy Insiders Buy In While Analysts Predict Big Upside Analysts Make a Quantum Bet on D-Wave's Cryogenic Packaging Yes, You Can Get Dividends in Tech: 3 Stocks With Yield + Upside MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
